上海交通大学学报（医学版）

›› 2012, Vol. 32 ›› Issue (12): 1646-.doi: 10.3969/j.issn.1674-8115.2012.12.026

• 综述 • 上一篇    下一篇

微小RNA在胰腺导管腺癌诊断、治疗和预后评估中的研究进展

张军峰, 花 荣   

  1. 上海交通大学 医学院附属仁济医院普外科, 上海 200127
  • 出版日期:2012-12-28 发布日期:2012-12-31
  • 通讯作者: 花 荣, 电子信箱: lordhuarong@sohu.com。
  • 作者简介:张军峰（1980—）, 男, 主治医师, 硕士生；电子信箱: zball2004@yeah.net。
  • 基金资助:

    上海市卫生局科研基金(2011213)

Research progress of microRNA in diagnosis, treatment and prognosis evaluation for pancreatic ductal adenocarcinoma

ZHANG Jun-feng, HUA Rong   

  1. Department of General Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China
  • Online:2012-12-28 Published:2012-12-31
  • Supported by:

    Shanghai Health Bureau Foundation, 2011213

PDF (PC)

1212

摘要：

微小RNA（miRNA）是一类非编码短链RNA，长度为17~25个核苷酸，在转录后水平调控基因表达。近年来研究发现miRNA在多个肿瘤的发生、发展、侵袭及转移等方面起作用。胰腺导管腺癌（PDAC）是预后极差的恶性肿瘤，至今仍缺乏可靠的早期诊断标志物和有效的治疗方法。文章重点介绍异常的miRNA表达谱在PDAC诊断、治疗和预后评估中的相关研究进展。

关键词: 胰腺导管腺癌, 微小RNA, 肿瘤标志物, 诊断

Abstract:

MicroRNA (miRNA) are a class of short noncoding RNAs, with 17-25 nucleotides in length, which play a role in the regulation of gene expression at posttranscriptional level. Recent studies have revealed that miRNA may be associated with pathogenesis, progression, invasion and metastasis of tumors. Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer which is characterized by the absence of biomarkers for early diagnosis and effective strategies for therapeutic intervention. The current status of miRNA in diagnosis, treatment and prognosis evaluation for PDAC is introduced in this paper.

Key words: pancreatic ductal adenocarcinoma, microRNA, tumor biomarker, diagnosis